We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 09, 2020

Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel–Trastuzumab in Uterine Serous Carcinomas

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Randomized Phase II Trial of Carboplatin–Paclitaxel Compared With Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas That Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Clin. Cancer Res 2020 Jun 29;[EPub Ahead of Print], AN Fader, DM Roque, E Siegel, N Buza, P Hui, O Abdelghany, S Chambers, AA Secord, L Havrilesky, DM O'Malley, FJ Backes, N Nevadunsky, B Edraki, D Pikaart, W Lowery, K ElSahwi, P Celano, S Bellone, M Azodi, B Litkouhi, E Ratner, DA Silasi, PE Schwartz, AD Santin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading